ScinoPharm to Invest in Tanvex Biologics

TAINAN, Taiwan, August 31, 2010 - ScinoPharm, a leading active pharmaceutical ingredient (API) developer
and manufacturer headquartered in Taiwan, today announced an investment into
Tanvex Biologics, Inc., a United States company registered in the State of
Delaware. ScinoPharm's investment was in the form of tangible assets,
intellectual properties, as well as cash.

Tanvex specializes in the development of biosimilars and biobetters, as
well as the provision of contract research and contract manufacturing
services for biologics. The company is currently establishing a cGMP facility
in San Diego, California and will have research centers in both the U.S. and
Taiwan. Tanvex is founded by Dr. Allen Chao, the founder and former Chairman
and Chief Executive Officer of Watson Pharmaceuticals, Inc.

Dr. Hardy Chan, co-founder and Chief Scientific Officer of ScinoPharm,
will become the Chief Executive Officer of Tanvex. Dr. Chao will remain as
Executive Chairman of Tanvex.

About ScinoPharm Taiwan

ScinoPharm Taiwan, Ltd. is a leading process R&D and API manufacturing
service provider to the global pharmaceutical industry. With research and
manufacturing facilities in both Taiwan and mainland China, ScinoPharm offers
a wide portfolio of services ranging from custom synthesis for early phase
pharmaceutical activities to brand companies as well as APIs for the generic
industry. For more information, please visit www.scinopharm.com .

About Tanvex Biologics

Tanvex Biologics, LLC is a US-based biopharmaceutical company
specializing in the development of biopharmaceuticals.

    Media Contact:
     ScinoPharm Taiwan, Ltd.
     Sabrina Wu
     Tel: +886-6-505-2869
     Mobile Phone: +886-920-056-385
     Email: sabrina.wu@scinopharm.com.tw

Sabrina Wu of ScinoPharm Taiwan, Ltd., +886-6-505-2869, +886-920-056-385, sabrina.wu at scinopharm.com.tw